Literature DB >> 31554637

Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma.

Krish Patel1, Alexey V Danilov2, John M Pagel1.   

Abstract

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma (FL) represent indolent malignancies characterized by multiple episodes of relapse. Therapy has centered on agents that largely target the B-cell receptor pathway. Duvelisib is a second-generation oral inhibitor of phosphoinositide-3 kinase, downstream of the B-cell receptor pathway, approved in the United States for relapsed CLL/SLL and FL. Duvelisib represents a highly active agent, and ongoing investigations, including fixed-duration drug combinations and alternative dosing schedules, are aimed at reducing immune-mediated toxicities.
© 2019 by The American Society of Hematology.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31554637     DOI： 10.1182/blood.2019001795

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  10 in total

Review 1.  When Glycosylation Meets Blood Cells: A Glance of the Aberrant Glycosylation in Hematological Malignancies.

Authors:  Huining Su; Mimi Wang; Xingchen Pang; Feng Guan; Xiang Li; Ying Cheng
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

Review 2.  Cell Death Pathways in Lymphoid Malignancies.

Authors:  Luke Fletcher; Edward Nabrinsky; Tingting Liu; Alexey Danilov
Journal:  Curr Oncol Rep       Date:  2020-01-27       Impact factor: 5.075

3.  A Ferroptosis Molecular Subtype-Related Signature for Predicting Prognosis and Response to Chemotherapy in Patients with Chronic Lymphocytic Leukemia.

Authors:  Han Gong; Heng Li; Qin Yang; Guangxiong Zhang; Hong Liu; Zekang Ma; Hongling Peng; Ling Nie; Xiaojuan Xiao; Jing Liu
Journal:  Biomed Res Int       Date:  2022-07-06       Impact factor: 3.246

4.  PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity.

Authors:  Christopher Ronald Funk; Shuhua Wang; Kevin Z Chen; Alexandra Waller; Aditi Sharma; Claudia L Edgar; Vikas A Gupta; Shanmuganathan Chandrakasan; Jaquelyn T Zoine; Andrew Fedanov; Sunil S Raikar; Jean L Koff; Christopher R Flowers; Silvia Coma; Jonathan A Pachter; Sruthi Ravindranathan; H Trent Spencer; Mala Shanmugam; Edmund K Waller
Journal:  Blood       Date:  2022-01-27       Impact factor: 25.476

Review 5.  Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors.

Authors:  Ashley Hanlon; Danielle M Brander
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 6.  Current and future treatment strategies in chronic lymphocytic leukemia.

Authors:  Krish Patel; John M Pagel
Journal:  J Hematol Oncol       Date:  2021-04-26       Impact factor: 17.388

Review 7.  Oral PI3K-δ,γ Inhibitor for the Management of People with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Narrative Review on Duvelisib.

Authors:  Ankit Shah; Jacqueline C Barrientos
Journal:  Onco Targets Ther       Date:  2021-03-25       Impact factor: 4.147

8.  RHOA G17V induces T follicular helper cell specification and involves angioimmunoblastic T-cell lymphoma via upregulating the expression of PON2 through an NF-κB-dependent mechanism.

Authors:  Fenglian Que; Lihong Zhang; Taoli Wang; Meifang Xu; Wangen Li; Shengbing Zang
Journal:  Oncoimmunology       Date:  2022-10-11       Impact factor: 7.723

9.  Inflammation and tumor progression: signaling pathways and targeted intervention.

Authors:  Huakan Zhao; Lei Wu; Guifang Yan; Yu Chen; Mingyue Zhou; Yongzhong Wu; Yongsheng Li
Journal:  Signal Transduct Target Ther       Date:  2021-07-12

Review 10.  Role of Non-Coding RNAs in the Development of Targeted Therapy and Immunotherapy Approaches for Chronic Lymphocytic Leukemia.

Authors:  Felice Pepe; Veronica Balatti
Journal:  J Clin Med       Date:  2020-02-21       Impact factor: 4.241
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.